Editas Medicine Inc
Company Profile
Business description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Contact
11 Hurley Street
CambridgeMA02141
USAT: +1 617 401-9000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
226
Stocks News & Analysis
stocks
Chart of the Week: The market may be underestimating Amcor’s long term potential
stocks
Competitive pressures highlight need to lower costs for big 4 bank
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,998.90 | 86.00 | -0.95% |
| CAC 40 | 8,241.24 | 85.01 | 1.04% |
| DAX 40 | 24,381.46 | 293.40 | 1.22% |
| Dow JONES (US) | 48,254.82 | 326.86 | 0.68% |
| FTSE 100 | 9,911.42 | 11.82 | 0.12% |
| HKSE | 26,922.73 | 226.32 | 0.85% |
| NASDAQ | 23,406.46 | 61.84 | -0.26% |
| Nikkei 225 | 51,058.90 | 4.41 | -0.01% |
| NZX 50 Index | 13,619.53 | 52.20 | -0.38% |
| S&P 500 | 6,850.92 | 4.31 | 0.06% |
| S&P/ASX 200 | 8,714.60 | 84.80 | -0.96% |
| SSE Composite Index | 4,000.14 | 2.62 | -0.07% |